Hepion Pharmaceuticals, Inc. (HEPA)

Market Cap	52.60M
Revenue (ttm)	n/a
Net Income (ttm)	-45.12M
Shares Out	76.23M
EPS (ttm)	-0.59
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,504
Open	0.700
Previous Close	0.682
Day's Range	0.671 - 0.700
52-Week Range	0.260 - 1.330
Beta	1.64
Analysts	Buy
Price Target	3.57 (+423.84%)
Earnings Date	Apr 14, 2023

About HEPA

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor bur...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D.
• Employees: 20
• Stock Exchange: NASDAQ
• Ticker Symbol: HEPA

Analyst Forecast

According to 9 analysts, the average rating for HEPA stock is "Buy." The 12-month stock price forecast is $3.57, which is an increase of 423.84% from the latest price.

Price Target

$3.57

(423.84% upside)

Analyst Consensus: Buy